Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

jin bin corporation sdn. bhd. - actinolitum; semen allium tuberosum; radix eurycoma longifolia; herba epimedium brevicornum; herba cynomorium songaricum.; herba cistanche deserticola.; fructus schisandra chinensis; fructus psoralea corylifolia; cortex eucommia ulmoides.; cortex cinnamomum cassia; semen cuscuta chinensis -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharco health sdn. bhd - lidocaine -

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,

Australia - English - Department of Health (Therapeutic Goods Administration)

grace global pty ltd - 56286 - nitrile examination/treatment glove, non-powdered - nitrile examination gloves non-sterile device made of nitrile intended as a protective barrier when worn on the hands of healthcare providers during patient examination/treatment or for other sanitary purposes; its inner surface is not covered with talcum powder. this is a single-use device.

Kenya - English - Pharmacy and Poisons Board

pt sanbe farma jl. industri cimareme no. 8 kompleks industri - tranexamic acid - transdermal gel - tranexamic acid 100 mg/ml - antihemorrhagics - antifibrinolytics: amino acids

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd -